Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
30.11.2023 17:37:00

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, HES, SIX, MIRO

NEW YORK, Nov. 30, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Halper Sadeh LLP (PRNewsfoto/Halper Sadeh LLP)

Mirati Therapeutics, Inc. (NASDAQ: MRTX)'s sale to Bristol Myers Squibb for $58.00 per share in cash. Additionally, Mirati shareholders will also receive one non-tradeable Contingent Value Right per Mirati share, entitling its holder to receive a one-time potential payment of $12.00 in cash upon acceptance by U.S. FDA of a new drug application for MRTX1719 for the treatment of either locally advanced or metastatic NSCLC in patients who have received no more than two prior lines of systemic therapy within seven years after the closing of the merger. If you are a Mirati shareholder, click here to learn more about your rights and options.

Hess Corporation (NYSE: HES)'s sale to Chevron Corporation for 1.0250 shares of Chevron for each Hess share. If you are a Hess shareholder, click here to learn more about your rights and options.  

Six Flags Entertainment Corporation (NYSE: SIX)'s sale to Cedar Fair for 0.5800 shares of common stock in the new combined company for each Six Flags share. Following the close of the proposed transaction, Six Flags shareholders will own approximately 48.8% of the combined company. If you are a Six Flags shareholder, click here to learn more about your rights and options.  

Miromatrix Medical Inc. (NASDAQ: MIRO)'s sale to United Therapeutics Corporation. Under the terms of the proposed transaction, United Therapeutics would acquire all outstanding shares of Miromatrix for $3.25 per share in cash and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's kidney product known as mirokidney™ by December 31, 2025. If you are a Miromatrix shareholder, click here to learn more about your rights and options.  

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-mrtx-hes-six-miro-302002137.html

SOURCE Halper Sadeh LLP

Analysen zu Hess Corpmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Hess Corp 142,02 0,32% Hess Corp